|Articles|February 20, 2008

L-acetylcarnitine Improves ADHD in Fragile X Syndrome

Treatment with L-acetylcarnitine may be beneficial in improving hyperactivity and social behavior in boys with fragile X syndrome who have attention-deficit/hyperactivity disorder (ADHD), according to an article published online Feb. 19 in the American Journal of Medical Genetics.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

ByJoshua Fitch, Senior Editor

November 25th 2025

FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury

ByMorgan Ebert, Managing Editor

November 14th 2025

Neurodevelopmental disorder risks not increased by prenatal acetaminophen use

ByCeleste Krewson, Assistant Editor

November 14th 2025

Genetic testing reveals key CNVs in affected children

ByMorgan Ebert, Managing Editor

November 13th 2025

Preterm birth linked to reduced odds of high school graduation

ByCeleste Krewson, Assistant Editor

October 21st 2025

Latest CME

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

L-acetylcarnitine Improves ADHD in Fragile X Syndrome

Newsletter

Related Content

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury

Neurodevelopmental disorder risks not increased by prenatal acetaminophen use

Genetic testing reveals key CNVs in affected children

Preterm birth linked to reduced odds of high school graduation

Latest CME

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

ACIP votes to update hepatitis B vaccine recommendation for infants

ASH data: Marstacimab improves bleeding outcomes in adolescents, adults with hemophilia A or B

FDA approves omidubicel-onlv as first HSCT therapy to treat severe aplastic anemia

Using genome and exome sequencing as early diagnostic tools, according to Christine Eng, MD

Hepatitis B Foundation president discusses recommendations for infant vaccination